Truist raised the firm’s price target on Merck to $122 from $116 and keeps a Buy rating on the shares after its Q2 results. The company’s base business is continuing to support growth as Merck executes on key products such as Keytruda/Gardasil, the analyst tells investors in a research note. Truist adds that it sees next leg of growth for the company coming from Cardiovascular Disease and Inflammation and Immunology programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK: